1. Experimental trials of predicted CD4+ and CD8+ T-cell epitopes of respiratory syncytial virus
- Author
-
Syeda Tahira Qousain Naqvi, Syed Aun Muhammad, Jinlei Guo, Sidra Zafar, Amjad Ali, Larry J. Anderson, Christina A. Rostad, and Baogang Bai
- Subjects
RSV ,prophylactic vaccine ,healthy and diseased animal models ,hematological and cellular assays ,virus neutralization assay ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundRespiratory syncytial virus (RSV) is the most common cause of viral lower respiratory tract infections (LRTIs) in young children around the world and an important cause of LRTI in the elderly. The available treatments and FDA-approved vaccines for RSV only lessen the severity of the infection and are recommended for infants and elderly people.MethodsWe focused on developing a broad-spectrum vaccine that activates the immune system to directly combat RSV. The objective of this study is to identify CD4+ and CD8+ T-cell epitopes using an immunoinformatics approach to develop RSV vaccines. The efficacy of these peptides was validated through in-vitro and in-vivo studies involving healthy and diseased animal models. ResultsFor each major histocompatibility complex (MHC) class-I and II, we found three epitopes of RSV proteins including F, G, and SH with an antigenic score of >0.5 and a projected SVM score of
- Published
- 2024
- Full Text
- View/download PDF